This trial is active not recruiting!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
4Get in touch
More info
You can access this
clinical trial
if you have
Sarcoma, Ovarian Neoplasm, Central Nervous System Neoplasm, Thyroid Neoplasm, Carcinoma, Neuroendocrine, Neoplasms, Germ Cell and Embryonal or NK/T-cell Lymphoma
and you are
over 15
years old
This is a second phase trial assessing
efficacy and side effects of the new treatment.
Show me locations

The purpose

This is a Phase 2, non-randomised, open-label, multicentric study to investigate the efficacy and safety of pembrolizumab monotherapy in 7 cohorts of patients with specific rare cancers who have unresectable locally advanced or metastatic disease, which is resistant or refractory to standard therapy, or for which standard therapy does not exist, or is not considered appropriate, and for which no other experimental treatment options are available, in order to identify subsets of patients that may benefit from treatment

Provided treatments

  • Drug: Pembrolizumab

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT03012620. The sponsor of the trial is UNICANCER and it is looking for 334 volunteers for the current phase.
Official trial title:
Secured Access to Pembrolizumab for Patients With Selected Rare Cancer Types